Get the Stockscreener App
0.1475
3.15%
-0.0048
Pre-market:
.14
-0.0075
-5.08%
Vincerx Pharma Inc stock is traded at $0.1475, with a volume of 2.30M.
It is down -3.15% in the last 24 hours and down -28.78% over the past month.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
See More
Previous Close:
$0.1523
Open:
$0.1507
24h Volume:
2.30M
Relative Volume:
0.35
Market Cap:
$5.38M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.0639
EPS:
-2.31
Net Cash Flow:
$-46.25M
1W Performance:
-13.59%
1M Performance:
-28.78%
6M Performance:
-77.31%
1Y Performance:
-86.21%
1-Day Range:
$0.1404
$0.152
1-Week Range:
$0.1395
$0.1743
52-Week Range:
$0.1395
$9.3722
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650-800-6676
Address
260 SHERIDAN AVENUE, PALO ALTO
Compare VINC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.1475 | 5.38M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Vincerx Pharma enters at-the-market equity offering deal - MSN
Vincerx Pharma enters at-the-market equity offering deal By Investing.com - Investing.com UK
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
VINC Stock Touches 52-Week Low at $0.17 Amid Market Challenges - Investing.com UK
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders - GlobeNewswire Inc.
Investor law firms question biotech merger's 'fairness' - The Business Journals
What Did We Find About Insider Trading At Vincerx Pharma Inc (NASDAQ: VINC)? - Stocks Register
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders - Stockhouse Publishing
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - Stockhouse Publishing
Vincerx Pharma Inc (NASDAQ: VINC): On Track To A Higher Share Price - Stocks Register
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders - The Malaysian Reserve
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerVINC, VCSA, MRNS, MHLD - Markets Insider
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders - Business Wire
Stock market today: Intrusion surged by 123.33% while Snow Lake Resources plunged by 21.88% in early trading - Business Upturn
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - MSN
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx Pharma Announces Merger, Leadership Changes, and Financing - TipRanks
Vincerx Pharma To Be Acquired by Private Biotech, Cut Headcount - MarketWatch
Vincerx Pharma enters binding term sheet for merger with Oqory - TipRanks
Psyence Biomed Announces Closing of $2.0 Million Private Placement - The Manila Times
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - GlobeNewswire
VINC Stock Touches 52-Week Low at $0.18 Amid Market Challenges - Investing.com UK
FDA Approvals News Live Feed - StockTitan
Canadian Solar (NASDAQ:CSIQ) Shares Gap Up – Here’s What Happened - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Down Following Analyst Downgrade - Defense World
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World
WaFd, Inc (NASDAQ:WAFDP) Short Interest Down 23.6% in November - Defense World
Vinci Partners Investments Ltd. (NASDAQ:VINP) Sees Significant Growth in Short Interest - Defense World
Full Stock Market News from 2024-12-14 - StockTitan
Vincerx Pharma announces workforce reduction of 55%, cost-control measures - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.24 Amid Market Challenges - Investing.com UK
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Asianet Newsable
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of Vip943 - Marketscreener.com
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 - GlobeNewswire
Vincerx Pharma Reports Promising Cancer Drug Results, Explores Strategic Options Amid Cost Cuts - StockTitan
DelveInsight Business Research, LLP: Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - finanznachrichten.de
Companies To Watch: Terns Pharmaceuticals - Life Science Leader Magazine
Vincerx Pharma gets extension to meet Nasdaq listing criteria - Investing.com
Vincerx Pharma gets extension to meet Nasdaq listing criteria By Investing.com - Investing.com UK
Recursion Completes Exscientia Merger, Creates AI Drug Discovery Powerhouse with $20B+ Pipeline - StockTitan
Leerink Partnrs Weighs in on Vincerx Pharma FY2024 Earnings - Defense World
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - Quartz
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus.com
Vincerx Pharma Reports Q3 2024 Financial Results - TipRanks
Vincerx Pharma Inc reports results for the quarter ended September 30Earnings Summary - XM
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):